Scientists have revealed a new system referred to as the Atlas system that makes it possible to detect Chlamydia infections within 30 minutes, latest reports indicate.
A company known as Atlas Genetics is behind a new system that allows physicians to detect any infections caused by Chlamydia within 30 minutes. The spin-out biotechnology firm working under the University of Bath was recently endorsed by the European Union (EU) to begin the rollout and sell of the kit that will detect Chlamydia, a sexually transmitted disease.
According to the World Health Organisation (WHO) there has been a rise in the cases of sexually transmitted infections (STIs) all over the world and Chlamydia ranks among the top. In its most recent report it is estimated that there are 499 million new cases every year, and unless effective measures are taken the war against STIs will be lost.
The Atlas system has been under development and testing for a long time and its approval signals new hope for victims of sexually transmitted infections. The current detection systems in the market though effective usually take a longer time and a patient may have to go through several examinations. This is not only time consuming but also an inconvenience to the patients.
According to lead researchers Dr Toby Jenkins and Professor Chris Frost , who both work at the Chemistry Department in the University of Bath, slow detection contributes to the surge in cases as victims have to wait for long to know their status while some simply avoid the process.
The Atlas system is much easier to carryout and the patient will know whether she has Chlamydia infection in matter of minutes and only one visit to a medical centre or clinic is required. In addition to quick diagnosing, the newly launched system also allows a victim to start receiving medication immediately.
Professor Chris Frost who heads the Department of Chemistry at the University says quick and early detection is key to combating the infection and this is what the detection device aims to achieve.
By relying on DNA probes that work with bespoke electrochemical tags, the system discovers any infectious disease in a much faster and more accurate way.
John Clarkson, the CEO of Atlas Genetics is optimistic about the new device which he says is a key landmark for Atlas Genetics. The company will focus on commercializing the device while embarking on new techniques that will help deal with STIs.
The latest trend indicates that STIs cases are rising and unless they are easily and quickly detected, the rate of providing medication on time will be hampered and this is why devices such as the Atlas system bring new hope to victims.